Human hematopoietic-specific protein

Abstract

The invention relates to hHSP polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

What is claimed is:  
     
         1 . An isolated polynucleotide comprising a polynucleotide having at least 70% identity to a member selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2;    (b) a polynucleotide encoding a polypeptide comprising amino acid 1 to amino acid 167 set forth in SEQ ID NO:2    (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b); and    (d) a polynucleotide comprising at least 15 bases of the polynucleotide of (a), (b) or (c).    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid −22 to 167 of SEQ ID NO:2.  
     
     
         6 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid 1 to 167 of SEQ ID NO:2.  
     
     
         7 . An isolated polynucleotide comprising a polynucleotide which is 70% identical to a member selected from the group consisting of: 
 (a) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the human cDNA contained in the deposited clone:    (b) a polynucleotide which is complementary to the polynucleotide of (a); and    (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a) or (b).    
     
     
         8 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 1 to nucleotide 833.  
     
     
         9 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 108 to nucleotide 833.  
     
     
         10 . A vector comprising the DNA of  claim 2 .  
     
     
         11 . A host cell comprising the vector of  claim 10 .  
     
     
         12 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 11  the polypeptide encoded by said DNA.  
     
     
         13 . A process for producing a cell which expresses a polypeptide comprising genetically engineering the cell with the vector of  claim 10 .  
     
     
         14 . A polypeptide comprising a member selected from the group consisting of: 
 (a) a polypeptide having an amino acid sequence set forth in SEQ ID NO:2;    (b) a polypeptide comprising amino acid 1 to amino acid 167 of SEQ ID NO:2; and    (c) a polypeptide which is at least 70% identical to the polypeptide of (a) or (b).    
     
     
         15 . The polypeptide of  claim 14  wherein the polypeptide comprises amino acid −22 to amino acid 167 of SEQ ID NO:2.  
     
     
         16 . The polypeptide of  claim 14  wherein the polypeptide comprises amino acid 1 to amino acid 167 of SEQ ID NO:2.  
     
     
         17 . A compound which inhibits activation of the polypeptide of  claim 14 .  
     
     
         18 . A compound which activates the polypeptide of  claim 14 .  
     
     
         19 . A method for the treatment of a patient having need of hHSP comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 14 .  
     
     
         20 . The method of  claim 19  wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         21 . A method for the treatment of a patient having need to inhibit a hHSP polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of  claim 17 .  
     
     
         22 . A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of  claim 14  comprising: 
 determining a mutation in a nucleic acid sequence encoding said polypeptide.  
 
     
     
         23 . A diagnostic process comprising: 
 analyzing for the presence of the polypeptide of  claim 14  in a sample derived from a host.    
     
     
         24 . A method for identifying compounds which inhibit or enhance activation of the polypeptide of  claim 14  comprising: contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable hHSP polypeptide and a compound under conditions to permit binding to the receptor; and 
 determining whether the compound inhibits or enhances the receptor by detecting the absence of a signal generated from the interaction of the hHSP with the receptor.  
 
     
     
         25 . An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of: 
 (a) a protein consisting of amino acid residues (−)22 to 167 of SEQ ID NO:2;    (b) a protein consisting of amino acid residues 1 to 167 of SEQ ID NO:2;    (c) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and    (d) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.    
     
     
         26 . The antibody or fragment thereof of  claim 25  that specifically binds protein (a).  
     
     
         27 . The antibody or fragment thereof of  claim 25  that specifically binds protein (b).  
     
     
         28 . The antibody or fragment thereof of  claim 25  that specifically binds protein (c).  
     
     
         29 . The antibody or fragment thereof of  claim 25  that specifically binds protein (d).  
     
     
         30 . The antibody or fragment thereof of  claim 26  that specifically binds protein (b).  
     
     
         31 . The antibody or fragment thereof of  claim 27  wherein said protein bound by said antibody or fragment thereof is glycosylated.  
     
     
         32 . The antibody or fragment thereof of  claim 27  which is a human antibody.  
     
     
         33 . The antibody or fragment thereof of  claim 27  which is a polyclonal antibody.  
     
     
         34 . The antibody or fragment thereof of  claim 27  which is a monoclonal antibody.  
     
     
         35 . The antibody or fragment thereof of  claim 27  which is selected from the group consisting of: 
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody;  
 (d) a Fab fragment;  
 
     
     
         36 . The antibody or fragment thereof of  claim 27  which is labeled.  
     
     
         37 . The antibody of  claim 36  wherein the label is selected from the group consisting of: 
 (a) an enzyme;  
 (b) a fluorescent label; and  
 (c) a radioisotope.  
 
     
     
         38 . The antibody or fragment thereof of  claim 27  wherein said antibody specifically binds to said protein in a Western blot.  
     
     
         39 . The antibody or fragment thereof of  claim 27  wherein said antibody specifically binds to said protein in an ELISA.  
     
     
         40 . An isolated cell that produces the antibody or fragment thereof of  claim 27 .  
     
     
         41 . A hybridoma that produces the antibody or fragment thereof of  claim 27 .  
     
     
         42 . A method of detecting hHSP protein in a biological sample comprising: 
 (a) contacting a biological sample with the antibody or fragment thereof of claim  27 ; and    (b) detecting the hHSP protein in the biological sample.    
     
     
         43 . The method of  claim 42  wherein the antibody or fragment thereof is a polyclonal antibody.  
     
     
         44 . An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of: 
 (a) a protein comprising the amino acid sequence of amino acid residues (−)22 to 167 of SEQ ID NO:2;    (b) a protein comprising the amino acid sequence of amino acid residues 1 to 167 of SEQ ID NO:2;    (c) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of SEQ ID NO:2; and    (d) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues of SEQ ID NO:2;    wherein said antibody or fragment thereof specifically binds to said amino acid sequence.    
     
     
         45 . The antibody or fragment thereof of  claim 44  obtained from an animal immunized with protein (a).  
     
     
         46 . The antibody or fragment thereof of  claim 44  obtained from an animal immunized with protein (b).  
     
     
         47 . The antibody or fragment thereof of  claim 44  obtained from an animal immunized with protein (c).  
     
     
         48 . The antibody or fragment thereof of  claim 44  obtained from an animal immunized with protein (d).  
     
     
         49 . The antibody or fragment thereof of  claim 44  which is a monoclonal antibody.  
     
     
         50 . The antibody or portion thereof of  claim 44  which is selected from the group consisting of: 
 (a) a chimeric antibody;  
 (b) a polyclonal antibody;  
 (c) a humanized antibody;  
 (d) a single chain antibody; and  
 (e) a Fab fragment.  
 
     
     
         51 . An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of: 
 (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455;    (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455;    (c) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455, wherein said portion comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455; and    (d) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455, wherein said portion comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455.    
     
     
         52 . The antibody or fragment thereof of  claim 51  that specifically binds protein (a).  
     
     
         53 . The antibody or fragment thereof of  claim 51  that specifically binds protein (b).  
     
     
         54 . The antibody or fragment thereof of  claim 51  that specifically binds protein (c).  
     
     
         55 . The antibody or fragment thereof of  claim 51  that specifically binds protein (d).  
     
     
         56 . The antibody or fragment thereof of  claim 52  that specifically binds protein (b).  
     
     
         57 . The antibody or fragment thereof of  claim 53  wherein said protein bound by said antibody or fragment thereof is glycosylated.  
     
     
         58 . The antibody or fragment thereof of  claim 53  which is a human antibody.  
     
     
         59 . The antibody or fragment thereof of  claim 53  which is a polyclonal antibody.  
     
     
         60 . The antibody or fragment thereof of  claim 53  which is a monoclonal antibody.  
     
     
         61 . The antibody or fragment thereof of  claim 53  which is selected from the group consisting of: 
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody; and  
 (d) a Fab fragment.  
 
     
     
         62 . The antibody or fragment thereof of  claim 53  which is labeled.  
     
     
         63 . The antibody of  claim 62  wherein the label is selected from the group consisting of: 
 (a) an enzyme;  
 (b) a fluorescent label; and  
 (c) a radioisotope label.  
 
     
     
         64 . The antibody or fragment thereof of  claim 53  wherein said antibody specifically binds to said protein in a Western blot.  
     
     
         65 . The antibody or fragment thereof of  claim 53  wherein said antibody specifically binds to said protein in an ELISA.  
     
     
         66 . An isolated cell that produces the antibody or fragment thereof of  claim 53 .  
     
     
         67 . A hybridoma that produces the antibody or fragment thereof of  claim 53 .  
     
     
         68 . A method of detecting hHSP protein in a biological sample comprising: 
 (a) contacting a biological sample with the antibody or fragment thereof of claim  53 ; and    (b) detecting the hHSP protein in the biological sample.    
     
     
         69 . The method of  claim 68  wherein the antibody or fragment thereof is a polyclonal antibody.  
     
     
         70 . An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of: 
 (a) a protein comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455;    (b) a protein comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455;    (c) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455; and    (d) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97455;    wherein said antibody or fragment thereof specifically binds to said amino acid sequence.    
     
     
         71 . The antibody or fragment thereof of claim  70  obtained from an animal immunized with protein (a).  
     
     
         72 . The antibody or fragment thereof of claim  70  obtained from an animal immunized with protein (b).  
     
     
         73 . The antibody or fragment thereof of claim  70  obtained from an animal immunized with protein (c).  
     
     
         74 . The antibody or fragment thereof of claim  70  obtained from an animal immunized with protein (d).  
     
     
         75 . The antibody or fragment thereof of claim  70  which is a monoclonal antibody.  
     
     
         76 . The antibody or portion thereof of claim  70  which is selected from the group consisting of: 
 (a) a chimeric antibody;  
 (b) a polyclonal antibody;  
 (c) a humanized antibody;  
 (d) a single chain antibody; and  
 (e) a Fab fragment.